受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | |
化学式 | C26H28F3N7O2 |
|||
分子量 | 527.54 | CAS No. | 2222635-15-4 | |
Solubility (25°C)* | 体外 | DMSO | 95 mg/mL (180.08 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | DCLK1-IN-1 is a selective, in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1) domain that binds to DCLK1 and DCLK2 with IC50 of 9.5 nM and 31 nM, respectively. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases with IC50 of 57.2 nM and 103 nM in kinase assay, respectively. |
---|---|
in vitro | DCLK1-IN-1 displays pronounced on-target DCLK1 activity in vitro. DCLK1-IN-1 potently binds DCLK1 in HCT116 cells (IC50 = 279 nM). DCLK1-IN-1 significantly inhibits DCLK1, and weakly inhibits ERK5, in PATU-8988T cell lysates and live cells.[1] |
in vivo | DCLK1-IN-1 has a favorable pharmacokinetic profile in mice, with a half-life of 2.09 h, an area under the curve of 5,506 h ng−1 ml−1 and 81% oral bioavailability. DCLK1-IN-1 is well-tolerated at doses up to 100 mg kg−1 with no adverse effects and no loss of body weight observed in mice. DCLK1-IN-1 is a selective inhibitor of DCLK1, suitable for use as a chemical probe when used together with control compound DCLK1-NEG.[1] |
細胞アッセイ | 細胞株 | PATU-8988T, PATU-8902, MIA PaCa-2, Panc03.27, CFPAC-1, BxPC-3, 293FT, HEK-293, HCT116 cells |
---|---|---|
濃度 | 1 μM, 2.5 μM | |
反応時間 | 4 h, 24 h | |
実験の流れ | For RNA-sequencing studies, PATU-8988T cells are plated at 200,000 cells per well in six-well plates. After adhering overnight, cells are treated with DMSO or 2.5 μM DCLK1-IN-1, washed twice with PBS, lysed and homogenized using Qiashredder columns. |
|
動物実験 | 動物モデル | 8–12-week-old male swiss albino mice |
投薬量 | 2 mg/kg, 10 mg/kg | |
投与方法 | IV, Oral gavage |
Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness [ Clin Transl Med, 2022, 12(5):e743] | PubMed: 35522902 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。